• Investors
  • News
  • Contact
Iconovo
  • About us
    • Board of Directors
    • Management
    • Our Team
    • Sustainability
    • Career
    • Investors
  • Inhalers
    • Inhalers
    • ICOres
    • ICOcap
    • ICOpre
    • ICOone
    • ICOone Nasal
    • Patents
  • Development capabilities
    • Development capabilities
    • Inhalers
    • Formulation
    • Pharmaceutical Analysis
    • Advisory services
  • Pipeline
  • Partner with us
    • Partner with us
    • Access our inhalers
  • Insights
    • Systemic Delivery of Biologics via Inhalation
    • Replacing injections with inhalation
    • Boost your business with an innovative inhaler partner
  • Investors
  • Search
  • Menu Menu

    Initial Public Offering (IPO) 2018 (Only in Swedish)

    March 2, 2018/in News /by Eva Norell

    Läs om Iconovos teckningserbjudande här.

    Share this entry
    • Share on Twitter
    • Share on LinkedIn
    • Share by Mail
    https://www.iconovo.se/wp-content/uploads/2021/03/Breathtaking-innovation_Iconovo.png 0 0 Eva Norell https://www.iconovo.se/wp-content/uploads/2021/03/Breathtaking-innovation_Iconovo.png Eva Norell2018-03-02 14:49:422018-03-02 14:49:42Initial Public Offering (IPO) 2018 (Only in Swedish)

    Possessing a unique combination

    of engineering and pharma expertise, Iconovo can provide the optimal combination of customized inhalers and tailored formulations.

    ICONOVO AB

    VISITING ADDRESS
    Ideon, Delta 6 Lund
    Ideongatan 3B

    POSTAL ADDRESS
    Iconovo AB
    Ideongatan 3A-B
    SE-223 70 LUND
    Sweden

    CONTACT

    Phone: +46 46 275 67 77

    VP Business Development
    Roger Lassing
    Mail: roger.lassing@iconovo.se

    CEO
    Johan Wäborg
    Mail: johan.waborg@iconovo.se

    Press releases

    Subscribe

    Follow us on Linkedin

    Annual Report 2017 (Only in Swedish) Iconovo are mentioned in Swedish business media (Only in Swedish)
    Scroll to top